Investigator Sponsored Studies - Amgen
Investigator Sponsored Studies - Amgen supports external researchers’ clinical studies involving its products or disease areas of interest to advance science, clinical medicine, and patient care.
Funder: Amgen
Due Dates: Clinical proposals accepted through the ISS portal (no stated deadline)
Funding Amounts: Financial support, study product, or both, subject to a research agreement
Summary: Supports investigator-sponsored clinical research involving Amgen products or disease areas of interest to advance science, clinical medicine, and patient care.
Key Information: External sponsors retain sole responsibility for study conduct, regulatory oversight, and safety reporting.
Description
Amgen’s Investigator Sponsored Studies (ISS) program supports unsolicited, scientifically sound research initiated, developed, designed, and conducted by sponsors external to Amgen. Studies may involve licensed or unlicensed Amgen products or focus on a disease area of interest. Eligible work includes interventional and observational research, health economic studies, epidemiological research, and analyses of existing data.
Support decisions depend on scientific merit and alignment with Amgen’s therapeutic development strategies, product-specific strategies, and research interests. Priorities span bone health, cardiovascular disease, inflammation, hematology and oncology, nephrology, and rare disease. Research interests include disease burden and biology, treatment efficacy and safety, biomarkers, combinations and sequencing, and real-world evidence. Amgen expects results to be shared in appropriate scientific forums, including peer-reviewed publications.
